IceCure Medical Ltd. announced the publication of an independent study evaluating its cryoablation system ProSense titled: ?CT-Guided Percutaneous Cryoablation of Breast Cancer: A Single-Center Experience? in Cancers, a leading peer-reviewed oncology journal. The study, led by Principal Investigator Professor Thomas J. Vogl, was conducted at the Institute of Radiology and Nuclear Medicine, University Hospital Frankfurt, at Goethe University, Germany.

Professor Vogl commented, ?Liquid Nitrogen-based cryoablation was found to be a safe local treatment for breast cancer, with a low complication rate--in fact, none were observed in the study. The company experienced a very high complete ablation rate of 100%. Overall survival, progression free survival and local tumor control were all good, especially given the very heterogenous patient population.

The fact that this is a minimally invasive procedure that can be performed on an outpatient basis with excellent cosmetic results are clear advantages. The company look forward to further evaluations of cryoablation especially in comparison to other treatment modalities for early, recurrent and metastatic breast cancer?.